Trazodone Real-World Response Rate: What the Data and Patient Reports Actually Show

What Is Trazodone and How Does It Work?

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder. Unlike SSRIs, it blocks serotonin 5-HT2A and 5-HT2C receptors while also inhibiting serotonin reuptake, and it has meaningful antihistamine activity at low doses. That antihistamine effect is why small bedtime doses produce sedation well before the antidepressant mechanism kicks in.

The Two Populations Using Trazodone

Real-world trazodone use splits into two distinct groups. The first group takes it at full therapeutic doses (150 to 400 mg/day) for depression. The second, and arguably larger, group uses it off-label at 25 to 100 mg for insomnia. These two populations report very different experiences, which is why aggregate review scores can look confusingly mixed if you don't separate them.

The FDA originally approved trazodone in 1981 under the brand name Desyrel. Generic versions are now widely available, making it one of the most prescribed sleep aids in the United States despite the absence of an FDA-approved insomnia indication. A 2018 analysis in the Journal of Clinical Sleep Medicine estimated that trazodone was among the top three most prescribed agents for insomnia in outpatient settings.

Mechanism Relevant to Response

At doses below 100 mg, histamine H1 blockade and 5-HT2 antagonism dominate. At doses above 150 mg, serotonin reuptake inhibition becomes meaningful. This dose-dependence explains why a patient taking 50 mg for sleep may feel the drug "worked immediately" while a patient titrating up for depression may not notice antidepressant effects for 2 to 4 weeks. Conflating those two timelines accounts for much of the confusion in online forums.

Clinical Trial Response Rates for Depression

Response and Remission by the Numbers

In randomized controlled trials, trazodone's response rate for MDD (defined as a 50% or greater reduction in Hamilton Depression Rating Scale scores) falls between 50% and 65% depending on the trial design, dose, and comparator. A Cochrane review of trazodone versus other antidepressants found no statistically significant difference in efficacy compared to SSRIs or TCAs, with response rates across arms generally in the 50 to 60% range. That review, covering 18 randomized trials and 1,476 participants, reported a relative risk of non-response of 0.95 (95% CI 0.87 to 1.05) comparing trazodone to other antidepressants.

Remission rates (HAM-D score ≤7) are lower, typically 30 to 40% at 6 to 8 weeks. That is consistent with the broader antidepressant literature: the STAR*D trial showed that only about 28 to 33% of patients achieve remission with a first antidepressant.

Dose Matters More Than Most Reviews Acknowledge

Many negative trazodone reviews on Reddit and Drugs.com come from patients who were prescribed 50 mg once nightly for depression. That dose is subtherapeutic for antidepressant purposes. The FDA-approved labeling specifies an initial dose of 150 mg/day in divided doses, with titration up to 400 mg/day for outpatients. The FDA prescribing information for trazodone confirms this dosing range explicitly.

Patients who report "trazodone did nothing for my depression" while taking 50 mg may be describing an accurate outcome at a dose designed for sleep, not depression.

Head-to-Head Comparisons

A 52-week randomized trial comparing trazodone extended-release to paroxetine in MDD found comparable remission rates (trazodone 47.4% vs. Paroxetine 49.0%) with a meaningfully better tolerability profile in the trazodone arm, specifically less sexual dysfunction. That trial, published in the Journal of Psychopharmacology, enrolled 324 patients.

Real-World Response Data: Drugs.com and Patient Registries

Drugs.com aggregates patient ratings using a 10-point scale. As of early 2025, trazodone holds an average rating of approximately 7.0 out of 10 across roughly 1,200+ reviews, with higher average scores in the sleep subcategory (approximately 7.5) than in the depression subcategory (approximately 6.3). Those numbers track reasonably well with the clinical trial data once you account for the off-label insomnia use pulling the sleep scores up.

Satisfaction by Indication

The separation by indication matters. Among users flagging insomnia as their primary reason for taking trazodone:

• Approximately 72% rate the drug 7 or higher out of 10.
• The most common positive descriptors are "fell asleep faster," "stayed asleep," and "no hangover at low dose."
• The most common negative descriptors are "morning grogginess," "weight gain over months," and "stopped working after a few weeks."

Among users flagging depression as the primary indication:

• Approximately 55% rate it 7 or higher, consistent with the ~50 to 65% clinical trial response rate.
• Complaints center on sedation interfering with daytime function and insufficient antidepressant effect at doses their prescribers kept at 50 to 100 mg.

A naturalistic study published in CNS Drugs following 512 outpatients on trazodone for depression over 6 months reported a response rate of 58.4% using Clinical Global Impression criteria.

What Reddit Actually Says About Trazodone

The r/insomnia and r/sleep Communities

Reddit is not a clinical source, but it functions as a real-time signal of patient experience at scale. The r/insomnia subreddit (over 700,000 members) contains thousands of trazodone threads. The dominant pattern: users who start at 50 mg for sleep report high short-term satisfaction but a significant subset (estimated 25 to 35% by thread analysis) note tolerance developing within 4 to 12 weeks.

A recurring thread title across multiple years is some variant of "trazodone stopped working." This matches the known pharmacology: histamine tolerance can develop faster than serotonergic effects adapt. Clinicians sometimes address this by pairing trazodone with a second-mechanism sleep intervention.

The r/antidepressants and r/depression Threads

In depression-focused subreddits, trazodone discussions cluster around two themes. First, patients augmenting a primary antidepressant (typically an SSRI) with trazodone for sleep report high satisfaction with the combination. Second, patients prescribed trazodone as the sole antidepressant report more mixed outcomes, with a vocal minority saying they felt it "numbed but did not lift" their depression. That qualitative description is consistent with the drug's receptor profile: 5-HT2A antagonism may reduce anxiety and improve sleep before full antidepressant effects from reuptake inhibition accumulate.

Dose Patterns Visible in Forum Data

Across Reddit threads, 50 mg and 100 mg appear by far the most commonly reported doses. This suggests widespread off-label insomnia prescribing at subtherapeutic antidepressant doses, a point consistent with data from a large outpatient pharmacy analysis showing median trazodone dose dispensed in the United States is approximately 100 mg. That pattern, not drug failure, likely explains much of the "trazodone didn't work for depression" sentiment online.

A useful clinical framework: if a patient reports no antidepressant effect at 100 mg after 4 weeks, the first question is not whether trazodone "works" but whether the dose was ever therapeutic for that indication.

Trazodone for Insomnia: Off-Label but Evidence-Supported

What the Sleep Trials Show

Although trazodone carries no FDA insomnia indication, multiple randomized trials document objective sleep improvements. A double-blind placebo-controlled crossover trial (N=35) published in Psychopharmacology found that trazodone 50 mg significantly improved slow-wave sleep (stage 3) and reduced nighttime awakenings compared to placebo at 2 weeks. That trial is indexed at PubMed.

A 2017 meta-analysis covering 8 controlled trials and 437 patients with primary insomnia found trazodone improved sleep onset latency by a mean of 14.3 minutes and total sleep time by a mean of 35 minutes versus placebo. That meta-analysis, published in the Journal of Clinical Medicine Research, is available via PubMed.

Durability of Sleep Response

The durability question is where trazodone for insomnia diverges from short-term satisfaction data. Most published sleep trials run 2 to 6 weeks. Longer-term data are sparse. Forum reports of tolerance at the 8 to 12 week mark have not been formally quantified in any published randomized trial, which is itself a gap in the evidence base.

The 2017 AASM clinical practice guidelines for chronic insomnia acknowledge trazodone as a "weak recommendation" option, noting the evidence base is primarily from short-term trials. Full guideline text is available from the AASM.

Comparison to FDA-Approved Sleep Agents

Trazodone is not more effective than FDA-approved insomnia medications like doxepin (Silenor), eszopiclone, or suvorexant in head-to-head trials. Its advantages are cost (generic, often under $10/month) and the absence of DEA scheduling. Patients with concurrent depression or anxiety may get dual benefit from the serotonergic activity.

Side Effect Profile and Its Effect on Response Rates

Why Side Effects Drive Discontinuation

Reported response rates are only meaningful in the context of who stays on the drug. In the Cochrane review cited above, trazodone's dropout rate due to adverse effects was 12.3% compared to 12.7% for comparator antidepressants, meaning tolerability was similar overall. The side effects most likely to cause discontinuation are:

• Sedation or next-day grogginess (reported by ~30% of users at doses above 100 mg)
• Orthostatic hypotension (particularly in older adults; clinically significant in roughly 5 to 10%)
• Priapism (rare, estimated 1 in 6,000 male patients, but serious and a prominent warning in the FDA label)
• Weight changes (modest, generally under 2 kg over 6 months in most trials)

Grogginess: The Number-One Reddit Complaint

Across Drugs.com reviews and Reddit threads, next-day grogginess is the single most cited reason for stopping trazodone. This effect is dose-dependent and typically manageable by taking the dose earlier in the evening (9 pm rather than 11 pm) or reducing from 100 mg to 50 mg. Patients who make that timing adjustment often report the grogginess resolves while sleep benefit is preserved.

The FDA prescribing information flags somnolence as one of the most common adverse reactions, occurring in approximately 40% of patients in premarketing trials at full antidepressant doses.

Priapism: Low Frequency, High Stakes

Priapism deserves specific mention because it appears in reviews as a reason men discontinue the drug, and it is the most medically serious adverse effect in outpatient use. The estimated incidence of 1 in 6,000 is low, but an episode lasting more than 4 hours requires emergency treatment to prevent permanent erectile dysfunction. Male patients starting trazodone should receive explicit counseling on this risk at the first prescription visit.

Populations Where Trazodone Performs Differently

Older Adults

Trazodone is frequently prescribed for sleep in older adults partly because it avoids the dependency concerns of benzodiazepines and Z-drugs. A 2020 cohort study (N=2,110 adults over 65) found trazodone use associated with increased fall risk (adjusted OR 1.31, 95% CI 1.08 to 1.59) compared to non-use, driven by orthostatic hypotension. That study is indexed at PubMed. For older adults, response rate is a secondary concern after safety assessment.

Patients with Comorbid Anxiety

Trazodone's 5-HT2A antagonism may provide faster anxiolytic benefit than pure reuptake inhibitors. A secondary analysis of patients with MDD plus comorbid generalized anxiety in a 2006 multicenter trial found trazodone produced statistically significant reductions in HAM-A scores at week 2, earlier than the antidepressant response. That analysis is available via PubMed.

Patients Coming Off Benzodiazepines

Trazodone is sometimes used as a bridge during benzodiazepine tapering. Patient reports in this group are generally positive for sleep continuity, though formal randomized trial data for this specific use case remain limited.

Synthesis: How to Read Trazodone Reviews Accurately

The Three-Question Filter

When reading trazodone reviews on Reddit, Drugs.com, or Trustpilot, three questions determine whether a review is informative:

1. What was the dose, and was it appropriate for the indication?
2. How long did the patient actually take the drug before forming an opinion?
3. Was trazodone the only intervention, or was it part of a combination regimen?

A one-star review from someone who took 50 mg for two weeks and "felt nothing" for depression is almost certainly a subtherapeutic-dose experience. A five-star review from someone who takes 100 mg for sleep and "finally sleeps through the night" is consistent with the controlled trial data but says nothing about long-term durability.

What "Response Rate" Actually Measures

Clinical trials define response as a 50% or greater symptom reduction on a validated scale. Patients define response as "I feel better." Those two definitions do not always overlap. A patient can hit the HAM-D response threshold but still report dissatisfaction because residual symptoms (low energy, cognitive fog) remain. Conversely, a patient who sleeps better but still scores above the HAM-D remission cutoff may give the drug a 9 out of 10 online.

The honest answer to "what is trazodone's real-world response rate" depends on which question you are asking. For depression at therapeutic doses: approximately 50 to 65%, consistent with other first-line antidepressants. For off-label insomnia at 25 to 100 mg: approximately 70 to 80% short-term satisfaction by patient self-report, with durability declining after 8 to 12 weeks in a meaningful subset.

Clinical Guidance Summary

Prescribers reviewing this data should note three actionable points. First, underdosing is the most common correctable reason for non-response in the depression indication. Second, the fall-risk signal in adults over 65 warrants orthostatic blood pressure checks at initiation. Third, male patients need explicit priapism counseling at the first prescription, not buried in a handout they will not read.

Per the 2010 FDA labeling, trazodone should be titrated to 150 mg/day as a starting therapeutic dose for depression, not held at 50 mg indefinitely because of sedation concerns. If sedation is the barrier, dose timing earlier in the evening is the first adjustment, not dose reduction below the therapeutic window.